Combo Therapy Shows Mixed Results for SSc-Related Lung Disea

A study of mycophenolate mofetil alone and in combination with pirfenidone for scleroderma-related interstitial lung disease showed mixed results.

Related Keywords

New York , United States , Ann Arbor , Michigan , Hospital For Special Surgery , Philadelphia , Pennsylvania , Abbvie Abbott , Dinesh Khanna , Genentech Roche , Robert Spiera , Bristol Myers Squibb , Glaxosmithkline , Genentech , Boehringer Ingelheim , American College Of Rheumatology , Novartis , University Of Michigan , Pfizer , Janssen Global Services , Mitsubishi Tanabe Pharma Corp , Scleroderma Lung Study , American College , Faster Acting Combination , Special Surgery , Horizon Therapeutics United States , Prometheus Biosciences , Corbus Pharmaceutical , Scleroderma , Crest Syndrome , Lung , Interstitial Lung Disease , Lung Fibrosis , Pulmonary Fibrosis , Ibrosis Pulmonary , Patient Safety , Adverse Effects , Side Effects , Coronavirus , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Non Hodgkins Lymphoma , Healthcare And Medical Technology , Ealth And Medical Te ,